Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.43 |
| ▸ | RAD52 | P43351 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 6/20 | 0.42 |
| ▸ | DGKA | P23743 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15878661 | 0.92 | ALDH1A1 (0.48) | NAAAEPHX1TSHRHCAR2NPSR1 | |
| SCHEMBL28258674 | 0.91 | NAAA (0.48) | NAAAEPHX1TSHRHCAR2RAD52 | |
| SCHEMBL4337046 | 0.91 | NAAA (0.48) | NAAAEPHX1TSHRHCAR2RAD52 | |
| SCHEMBL4334853 | 0.91 | NAAA (0.48) | NAAAEPHX1TSHRHCAR2RAD52 | |
| SCHEMBL11074377 | 0.91 | NAAA (0.48) | NAAAEPHX1TSHRHCAR2RAD52 | |
| SCHEMBL4330071 | 0.91 | NAAA (0.48) | NAAAEPHX1TSHRHCAR2RAD52 | |
| SCHEMBL11076096 | 0.91 | NAAA (0.48) | NAAAEPHX1TSHRHCAR2RAD52 | |
| SCHEMBL4335705 | 0.91 | NAAA (0.48) | NAAAEPHX1TSHRHCAR2RAD52 | |
| SCHEMBL7781071 | 0.86 | NAAA (0.55) | NAAAEPHX1TSHRHCAR2RAD52 | |
| SCHEMBL7768452 | 0.86 | NAAA (0.55) | NAAAEPHX1TSHRHCAR2RAD52 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159926-A1 | BASE EDITING OF PCSK9 AND METHODS OF USING SAME FOR TREATMENT OF DISEASE | VERVE THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230159926-A1 | BASE EDITING OF PCSK9 AND METHODS OF USING SAME FOR TREATMENT OF DISEASE | VERVE THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230158174-A1 | CHEMICALLY MODIFIED GUIDE RNAS FOR GENOME EDITING WITH CAS9 | VERVE THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159926-A1 | BASE EDITING OF PCSK9 AND METHODS OF USING SAME FOR TREATMENT OF DISEASE | PCSK9, LDLR, PCSK7 | NAAA 2328/4885EPHX1 1863/4885TSHR 3211/4885 |
| US-20230158174-A1 | CHEMICALLY MODIFIED GUIDE RNAS FOR GENOME EDITING WITH CAS9 | LDLR, LIPC, SREBF2 | NAAA 3323/4885EPHX1 2245/4885TSHR 3388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.